FUNDING
Company Profile
Colossal Biosciences is a genetic engineering company working to de-extinct species like the woolly mammoth and dire wolf while commercializing spinout biotech applications.
Founded 2021Dallas, Texas$850M raised$10.3B valuation
Investors
TWG GlobalThomas TullMark WalterTim DraperWinklevoss CapitalIn-Q-TelARCH Venture PartnersTom Brady
Compare with
Colossal Biosciences FAQ
- What is Colossal Biosciences's valuation in 2026?
- Colossal Biosciences was last valued at $10.3B in its most recent funding round.
- How much has Colossal Biosciences raised?
- Colossal Biosciences has raised approximately $850M in total funding to date.
- Is Colossal Biosciences publicly traded?
- No. Colossal Biosciences is privately held, last valued at $10.3B.
- Who are Colossal Biosciences's investors?
- Colossal Biosciences's investors include TWG Global, Thomas Tull, Mark Walter, Tim Draper, Winklevoss Capital, In-Q-Tel, ARCH Venture Partners, Tom Brady.
Coverage Timeline
newest firstAll Coverage
FUNDING$20B-$30B talks
Colossal Biosciences in Talks to Raise at Up to $30B Valuation
Colossal Biosciences is reportedly in talks to raise new capital at a $20-30 billion valuation, up to triple its January 2025 mark, building revenue-generating spinouts beyond its mammoth and dire wolf projects.
FUNDING
Colossal Biosciences in Talks to Raise at $20B-$30B Valuation
FUNDING$20B-$30B valuation
Colossal Biosciences in Talks to Raise at $20B-$30B Valuation
De-extinction genetics company Colossal Biosciences is reportedly in talks to raise new capital at a $20 billion to $30 billion valuation, a dramatic step up that would make it one of the most valuable biotech startups in the world.